Welcome to our dedicated page for Myomo news (Ticker: MYO), a resource for investors and traders seeking the latest updates and insights on Myomo stock.
Myomo Inc. develops and markets wearable medical robotics for people with neurological disorders and upper-limb paralysis. Its MyoPro product line is a powered upper-limb orthosis that uses non-invasive EMG sensors to support weakened or paralyzed arms in patients with conditions such as stroke, brachial plexus injury, traumatic brain injury, spinal cord injury and other neuromuscular disease or injury.
Company news commonly covers MyoPro orders, insurance authorizations, patient-pipeline trends, revenue from recurring patient sources, market-access relationships with orthotics and prosthetics providers, and product-development updates such as the Myomo Mobile App. Updates also include clinical research evaluating MyoPro, operating results, direct-billing activity, international sales channels and board governance changes.
Myomo, Inc. (NYSE American: MYO) has announced agreements with warrant holders to exercise 1,015,798 shares at $5.00 each, generating approximately $5.1 million in gross proceeds. This exercise is crucial for increasing capital for the wearable medical robotics company, which aims to enhance functionality for those with neurological disorders and upper-limb paralysis. The company's MyoPro product line helps restore mobility to patients, enabling them to perform daily activities and potentially return to work.
Myomo, Inc. (NYSE American:MYO) announced participation in the Fall Harvest - Best Ideas From the Buy-Side conference from October 5-8, 2021. CEO Paul Gudonis and CFO David Henry will present on October 5 at 1:00 p.m. ET, with live webcasting available. One-on-one meetings can be scheduled during the conference. Myomo specializes in wearable medical robotics, focusing on assisting those with neurological disorders and upper-limb paralysis through its MyoPro product line.
For more details, visit www.myomo.com.
Myomo, Inc. (NYSE American: MYO) has secured patents for its advanced powered orthotic device in location value="LC/cn"China and location value="LC/hk"Hong Kong. The patents, effective until June 2036, will be licensed to a joint venture in China created with Beijing Ryzur Medical Investment Co., Ltd.. This venture aims to introduce Myomo's technology to the extensive Chinese market, which has approximately 14 million individuals with upper-arm paralysis. The CEO expressed optimism about becoming a standard care solution for these patients.
Myomo, Inc. (NYSE American:MYO), a company specializing in wearable medical robotics for neurological disorders and upper-limb paralysis, announced participation in three investment conferences in September 2021. These include the Colliers Institutional Investor Conference on September 9, the H.C. Wainwright Global Investment Conference from September 13-15, and the Oppenheimer Fall Healthcare Summit from September 20-23. Myomo's MyoPro device is the only one that restores arm function using the patient's own EMG signals, enabling independence for users.
Myomo, a wearable medical robotics company, reported significant financial growth for Q2 2021. Revenue reached $3.1 million, a 262% increase year-over-year, with 80 units sold, up 233%. Gross margin improved to 71%, up from 51% a year ago. Operating loss narrowed to $2.6 million from $2.8 million year-over-year. The backlog rose by 36% to 160 units. Management is optimistic for continued growth in Q3, driven by direct-to-patient marketing and expanding insurance coverage for MyoPro devices.
Myomo, Inc. (NYSE American: MYO) will report its financial results for the three and six months ended June 30, 2021 on August 9, 2021, after market close. A conference call will follow at 4:30 p.m. ET with remarks from CEO Paul R. Gudonis and CFO David Henry. Participants are encouraged to pre-register for immediate access. Myomo specializes in wearable medical robotics aimed at improving upper limb function in patients with neurological disorders and paralysis, featuring the MyoPro product line that utilizes EMG sensors for functionality restoration.
Myomo, Inc. (NYSE American: MYO) announced its accreditation by the Healthcare Quality Association on Accreditation (HQAA), confirming compliance with the Social Security Act requirements. This accreditation follows the Company’s authorization as a Medicare Provider by the Centers for Medicare & Medicaid Services (CMS). CEO Paul R. Gudonis highlighted that while reimbursement for MyoPro orthosis is approved on a case-by-case basis, broader coverage could enhance service for beneficiaries suffering from upper-limb paralysis. However, he emphasized that coverage terms from CMS are still pending.
Myomo, Inc. (NYSE American: MYO) has announced its participation in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021. This virtual event will allow investors to engage in one-on-one meetings with Myomo's management team. Myomo specializes in wearable medical robotics, particularly the MyoPro product line, which aids individuals with neurological disorders and upper-limb paralysis. The MyoPro device is unique for its ability to restore arm function using non-invasive EMG sensors, enabling users to perform daily activities and live independently.
Myomo, Inc. (NYSE American: MYO) announced its addition to the Russell Microcap® Index, effective today. This is a significant milestone aimed at raising the company's profile within the global investment community. Paul R. Gudonis, Myomo's representative, expressed enthusiasm about this inclusion, which enhances exposure to investment managers and institutions.
The membership in the Russell Microcap® Index lasts for one year, providing automatic inclusion in relevant growth and value indexes, which collectively benchmark approximately $10.6 trillion in assets.
Myomo, Inc. (NYSE American: MYO) will present a corporate overview at the Sidoti Virtual Investor Conference on June 23, 2021, from 10:45 a.m. to 11:15 a.m. Eastern Time. The presentation will be led by CEO Paul R. Gudonis and CFO David Henry. Interested investors can access the live webcast at sidoti.cventevents.com and the archived presentation will be available for 90 days on myomo.com. Myomo specializes in wearable medical robotics, enhancing functionality for those with neurological disorders.